Literature DB >> 14769808

Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats.

Akira Nishiyama1, Li Yao, Yukiko Nagai, Kayoko Miyata, Masanori Yoshizumi, Shoji Kagami, Shuji Kondo, Hideyasu Kiyomoto, Takatomi Shokoji, Shoji Kimura, Masakazu Kohno, Youichi Abe.   

Abstract

Studies were performed to test the hypothesis that reactive oxygen species (ROS) and mitogen-activated protein kinase (MAPK) contribute to the pathogenesis of aldosterone/salt-induced renal injury. Rats were given 1% NaCl to drink and were treated with one of the following combinations for 6 weeks: vehicle (0.5% ethanol, SC, n=6); aldosterone (0.75 microg/H, SC, n=8); aldosterone plus a selective mineralocorticoid receptor antagonist; eplerenone (0.125% in chow, n=8); aldosterone plus an antioxidant; and tempol (3 mmol/L in drinking solution, n=8). The activities of MAPKs, including extracellular signal-regulated kinases (ERK)1/2, c-Jun-NH2-terminal kinases (JNK), p38MAPK, and big-MAPK-1 (BMK1) in renal cortical tissues were measured by Western blot analysis. Aldosterone-infused rats showed higher systolic blood pressure (165+/-5 mm Hg) and urinary excretion of protein (106+/-24 mg/d) than vehicle-infused rats (118+/-3 mm Hg and 10+/-3 mg/d). Renal cortical mRNA expression of p22phox, Nox-4, and gp91phox, measured by real-time polymerase chain reaction, was increased in aldosterone-infused rats by 2.3, 4.3, and 3.0-fold, respectively. Thiobarbituric acid-reactive substances (TBARS) content in renal cortex was also higher in aldosterone (0.23+/-0.02) than vehicle-infused rats (0.09+/-0.01 nmol/mg protein). ERK1/2, JNK, and BMK1 activities were significantly elevated in aldosterone-infused rats by 3.3, 2.3, and 3.0-fold, respectively, whereas p38MAPK activity was not changed. Concurrent administration of eplerenone or tempol to aldosterone-infused rats prevented the development of hypertension (127+/-2 and 125+/-5 mm Hg), and the elevations of urinary excretion of protein (10+/-2 and 9+/-2 mg/day) or TBARS contents (0.08+/-0.01 and 0.11+/-0.01 nmol/mg protein). Furthermore, eplerenone and tempol treatments normalized the activities of ERK1/2, JNK, and BMK1. These data suggest that ROS and MAPK play a role in the progression of renal injury induced by chronic elevations in aldosterone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769808     DOI: 10.1161/01.HYP.0000118519.66430.22

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  91 in total

1.  PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice.

Authors:  Baojian Xue; Terry G Beltz; Ralph F Johnson; Fang Guo; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

Review 2.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

3.  Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.

Authors:  Wei Liang; Cheng Chen; Jing Shi; Zhilong Ren; Fengqi Hu; Harry van Goor; Pravin C Singhal; Guohua Ding
Journal:  Nephrol Dial Transplant       Date:  2010-08-20       Impact factor: 5.992

Review 4.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

5.  Aldosterone aggravates glucose intolerance induced by high fructose.

Authors:  Shamshad J Sherajee; Kazi Rafiq; Daisuke Nakano; Hirohito Mori; Hideki Kobara; Hirofumi Hitomi; Yoshihide Fujisawa; Hiroyuki Kobori; Tsutomu Masaki; Akira Nishiyama
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

6.  Interaction between nitric oxide and superoxide in the macula densa in aldosterone-induced alterations of tubuloglomerular feedback.

Authors:  Qian Zhang; Lin Lin; Yan Lu; Haifeng Liu; Yanhua Duan; Xiaolong Zhu; Chengwei Zou; R Davis Manning; Ruisheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

Review 7.  Mineralocorticoid receptor antagonists and hypertension: is there a rationale?

Authors:  Olga Gumieniak; Gordon H Williams
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

8.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 9.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

10.  Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat.

Authors:  Young Mee Park; Bong Hee Lim; Rhian M Touyz; Jeong Bae Park
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.